Barbara Pistilli

机构：Inserm, Université Paris-Saclay, Institut Gustave Roussy · ORCID：0000-0002-9184-7199

发表论文 360 篇 · 总被引 7103 次 · h-index 42

代表论文

• Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study (2026 · Cancer Cell · 被引 6)
• Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro. (2026 · Journal of Clinical Oncology · 被引 2)
• A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/ PIK3CA -mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2). (2026 · Journal of Clinical Oncology · 被引 2)
• Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study (2026 · Clinical Pharmacology & Therapeutics · 被引 1)
• Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC) (2026 · ESMO Open · 被引 1)
• Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer (2026 · Journal of Clinical Oncology · 被引 1)